Spark Therapeutics Inc (ONCE) Given Consensus Recommendation of “Buy” by Brokerages

Spark Therapeutics Inc (NASDAQ:ONCE) has been given a consensus rating of “Buy” by the twenty-two research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $76.03.

A number of brokerages recently issued reports on ONCE. Cantor Fitzgerald decreased their price objective on shares of Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating for the company in a report on Friday, October 13th. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial reaffirmed a “buy” rating and issued a $75.00 price target on shares of Spark Therapeutics in a research note on Thursday, December 7th. Barclays lifted their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of Spark Therapeutics in a research note on Friday, October 13th.

In other news, insider Daniel Faga sold 6,000 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the sale, the insider now owns 6,000 shares of the company’s stock, valued at $479,700. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Barge Joseph La sold 5,500 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the sale, the insider now directly owns 8,146 shares in the company, valued at approximately $581,950.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,309 shares of company stock worth $4,621,085. Insiders own 7.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in ONCE. Janus Henderson Group PLC bought a new stake in shares of Spark Therapeutics in the second quarter worth $30,848,000. Orbimed Advisors LLC bought a new stake in shares of Spark Therapeutics in the third quarter worth $38,340,000. Jennison Associates LLC bought a new stake in shares of Spark Therapeutics in the third quarter worth $27,239,000. JPMorgan Chase & Co. lifted its position in shares of Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Shares of Spark Therapeutics (NASDAQ ONCE) traded down $3.92 during midday trading on Friday, reaching $51.84. 1,785,400 shares of the company were exchanged, compared to its average volume of 1,199,500. The firm has a market capitalization of $1,840.00 and a PE ratio of -7.20. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.07) EPS. equities research analysts predict that Spark Therapeutics will post -7.58 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics Inc (ONCE) Given Consensus Recommendation of “Buy” by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/spark-therapeutics-inc-once-given-consensus-recommendation-of-buy-by-brokerages.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply